Zevra Therapeutics, Inc.ZVRANASDAQ
Loading
Other Income/Expenses (Net) Over TimeExpanding
Percentile Rank100
3Y CAGR+111.7%
Studio
Year-over-Year Change

Net other income and expenses outside core operations

3Y CAGR
+111.7%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
9.5x
Strong expansion
Streak
1 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$149.62M+4869.6%
2024$-3.14M-188.2%
2023$3.56M-77.4%
2022$15.76M+197.0%
2021$-16.25M-126.2%
2020$-7.18M-70.8%
2019$-4.21M-510.6%
2018$-689000.00+93.2%
2017$-10.06M-148.0%
2016$20.95M-